VistaGen Therapeutics Announces Receipt of $5 Million Non-Dilutive Upfront License Payment from EverInsight Therapeutics for PH94B Strategic Collaboration Aug 4, 2020
VistaGen Therapeutics Announces Pricing of $12.5 Million Underwritten Public Offering of Common Stock Aug 2, 2020
VistaGen Therapeutics Announces Positive Meeting with FDA Regarding Pivotal Phase 3 Study of PH94B for Acute Treatment of Anxiety in Patients with Social Anxiety Disorder Jul 23, 2020
VistaGen Therapeutics and EverInsight Therapeutics Enter Strategic Collaboration to Develop and Commercialize PH94B for Anxiety Disorders in Greater China, South Korea and Southeast Asia Jun 25, 2020
VistaGen and Nuformix Announce Agreement to Develop Novel Patentable Cocrystalline Forms of AV-101 for Treatment of Multiple CNS Conditions May 27, 2020
VistaGen Submits PH94B Phase 2A Study Protocol for Treatment of Adjustment Disorder with Anxiety Related to the COVID-19 Pandemic through U.S. FDA's Coronavirus Treatment Acceleration Program (CTAP) May 18, 2020
VistaGen Expands PH94B Clinical Development to Include Adjustment Disorder Related to COVID-19 Apr 28, 2020
VistaGen Therapeutics Announces Common Stock Purchase Agreement for up to $10.25 Million Mar 25, 2020
